M. Lewis

发表

First prospective comparison of genotypic versus phenotypic tropism assays in predicting virologic responses to maraviroc in a phase 3 study.

C. Craig, E. van der Ryst, J. Heera, 2019, The new microbiologica.

Genotypic Analysis of the V3 Region of HIV from Virologic Nonresponders to Maraviroc-Containing Regimens Reveals Distinct Patterns of Failure

P. Harrigan, H. Valdez, C. Chui, 2013, Antimicrobial Agents and Chemotherapy.

968 GENOTYPIC CHARACTERISATION OF HCV NS5B FOLLOWING 8-DAY MONOTHERAPY WITH THE POLYMERASE INHIBITOR PF-00868554 IN HCV-INFECTED SUBJECTS

P. Troke, M. Perros, C. Craig, 2009 .

Characterization of Resistance to the Nonnucleoside NS5B Inhibitor Filibuvir in Hepatitis C Virus-Infected Patients

P. Troke, C. Craig, M. Westby, 2011, Antimicrobial Agents and Chemotherapy.

Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc.

M. Jensen, P. Harrigan, D. Knapp, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry

G. Ciaramella, P. Dorr, M. Perros, 2006, Journal of Virology.

An Integrated Transcriptomic and Meta-Analysis of Hepatoma Cells Reveals Factors That Influence Susceptibility to HCV Infection

F. Chisari, D. Robertson, V. Lohmann, 2011, PloS one.

Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.

Alexander Thielen, M. Jensen, P. Harrigan, 2011, The Journal of infectious diseases.

The Evolutionary Analysis of Emerging Low Frequency HIV-1 CXCR4 Using Variants through Time—An Ultra-Deep Approach

David L. Robertson, Marilyn Lewis, Andrew Rambaut, 2010, PLoS Comput. Biol..

Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies

P. Harrigan, H. Valdez, A. Thielen, 2010, AIDS.

Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing

John Archer, David L Robertson, B. Taillon, 2009, AIDS.

Screening for HIV Tropism Using Population-based V3 Genotypic Analysis: A Retrospective Outcome Analysis Using Stored Plasma Screening Samples from MOTIVATE-1

M. Jensen, P. Harrigan, H. Valdez, 2009 .

Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor

Simon A. A. Travers, David L. Robertson, Xiaowei Jiang, 2015, Journal of Virology.

Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir

Mike Youle, M. Youle, J. Whitcomb, 2006, Journal of Virology.

Baseline CD4+ T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients

D. Kuritzkes, J. Schapiro, C. Boucher, 2011, Antiviral therapy.

Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naïve HIV patients screened for Study A4001078.

M. Däumer, H. Valdez, A. Thielen, 2013, Antiviral research.

Population-Based Sequencing of the V3-loop Can Predict the Virological Response to Maraviroc in Treatment-Naive Patients of the MERIT Trial

P. Harrigan, H. Valdez, A. Thielen, 2012, Journal of acquired immune deficiency syndromes.

Mutations in Gp41 are Correlated with Coreceptor Tropism but Do Not Improve Prediction Methods Substantially

Thomas Lengauer, P. Harrigan, H. Valdez, 2011, Antiviral therapy.

Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.

M. Churchill, S. Lewin, J. Flynn, 2017, AIDS research and human retroviruses.

Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials

D. Robertson, Wei Huang, J. Whitcomb, 2018, PloS one.

LENZILUMAB OUTCOMES ACCORDING TO RACE OF COVID-19 PARTICIPANTS IN THE LIVE-AIR PHASE 3 TRIAL

F. Cerasoli, Z. Temesgen, D. Chappell, 2022, medRxiv.

Population-Based Sequencing of the V3-loop Can Predict the Virological Response to Maraviroc in Treatment-Naive Patients of the MERIT Trial

H. Valdez, A. Thielen, C. Brumme, 2012, Journal of acquired immune deficiency syndromes.